.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Chinese Patent Office
Queensland Health
Fuji
McKinsey
Accenture
UBS
Healthtrust
Covington
Cerilliant

Generated: June 24, 2017

DrugPatentWatch Database Preview

CABERGOLINE Drug Profile

« Back to Dashboard

What is the patent landscape for Cabergoline, and what generic Cabergoline alternatives are available?

Cabergoline is a drug marketed by Apotex Corp, Par Pharm, Actavis Labs Fl Inc, Impax Labs Inc, Mylan Pharms Inc, and Ivax Sub Teva Pharms. and is included in six NDAs.

The generic ingredient in CABERGOLINE is cabergoline. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cabergoline profile page.

Summary for Tradename: CABERGOLINE

Patents:0
Applicants:6
NDAs:6
Suppliers / Packagers: see list5
Bulk Api Vendors: see list29
Clinical Trials: see list41
Patent Applications: see list2,220
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CABERGOLINE at DailyMed

Pharmacology for Tradename: CABERGOLINE

Ingredient-typeErgolines
Drug ClassErgot Derivative
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Corp
CABERGOLINE
cabergoline
TABLET;ORAL201503-001Mar 8, 2013ABRXNoNo► Subscribe► Subscribe
Impax Labs Inc
CABERGOLINE
cabergoline
TABLET;ORAL077843-001Jul 3, 2007DISCNNoNo► Subscribe► Subscribe
Par Pharm
CABERGOLINE
cabergoline
TABLET;ORAL076310-001Dec 29, 2005ABRXNoYes► Subscribe► Subscribe
Actavis Labs Fl Inc
CABERGOLINE
cabergoline
TABLET;ORAL078035-001Apr 21, 2008ABRXNoNo► Subscribe► Subscribe
Ivax Sub Teva Pharms
CABERGOLINE
cabergoline
TABLET;ORAL077750-001Mar 7, 2007ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Accenture
QuintilesIMS
UBS
Teva
Chinese Patent Office
Julphar
Cerilliant
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot